Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$0.86 +22.3%	$0.69	$0.45 ▼ $1.99	$52.74M	1.43	425,375 shs	6.25 million shs
ELDN Eledon Pharmaceuticals	$3.78 -1.8%	$3.03	$2.38 ▼ $5.54	$230.55M	-0.16	332,225 shs	519,150 shs
ESPR Esperion Therapeutics	$1.12 -0.9%	$1.02	$0.69 ▼ $3.94	$223.96M	0.7	4.70 million shs	2.20 million shs
TVGN Semper Paratus Acquisition	$1.23 +2.5%	$1.23	$0.26 ▼ $3.09	$220.67M	-0.73	5.07 million shs	317,524 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	+22.29%	+9.28%	+45.08%	+12.34%	-8.15%
ELDN Eledon Pharmaceuticals	-1.82%	+11.18%	+35.00%	+26.42%	+33.57%
ESPR Esperion Therapeutics	-0.88%	-8.94%	-4.27%	+17.89%	-58.97%
TVGN Semper Paratus Acquisition	+2.50%	-0.81%	-3.15%	+25.56%	+68.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CUE Cue Biopharma	4.2142 of 5 stars	3.5	2.0	4.7	3.8	0.8	0.6
ELDN Eledon Pharmaceuticals	1.8231 of 5 stars	3.5	1.0	0.0	2.8	1.7	0.0
ESPR Esperion Therapeutics	3.9253 of 5 stars	3.4	2.0	3.9	2.5	1.7	0.6
TVGN Semper Paratus Acquisition	4.0981 of 5 stars	3.5	5.0	0.0	1.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	3.00	Buy	$3.00	250.47% Upside
ELDN Eledon Pharmaceuticals	3.00	Buy	$9.00	138.10% Upside
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	525.00% Upside
TVGN Semper Paratus Acquisition	3.00	Buy	$10.00	713.01% Upside

Current Analyst Ratings Breakdown

Latest CUE, ELDN, ESPR, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ELDN Eledon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$9.00
6/18/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/10/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/27/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/12/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/29/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/21/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$9.29M	6.94	N/A	N/A	$0.28 per share	3.06
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.98 per share	N/A
ESPR Esperion Therapeutics	$332.31M	0.67	$0.02 per share	47.03	($1.97) per share	-0.57
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	($0.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$40.67M	-$0.67	N/A	N/A	N/A	-507.87%	-228.43%	-114.66%	8/13/2025 (Estimated)
ELDN Eledon Pharmaceuticals	-$36.18M	-$2.10	N/A	N/A	N/A	N/A	-79.54%	-41.62%	8/18/2025 (Estimated)
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
TVGN Semper Paratus Acquisition	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-934.56%	8/4/2025 (Estimated)

Latest CUE, ELDN, ESPR, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	CUE Cue Biopharma	-$0.13	N/A	N/A	N/A	$2.00 million	N/A
8/11/2025	Q2 2025	ESPR Esperion Therapeutics	-$0.17	N/A	N/A	N/A	$62.55 million	N/A
5/14/2025	Q1 2025	ELDN Eledon Pharmaceuticals	-$0.28	-$0.08	+$0.20	-$0.08	N/A	N/A
5/12/2025	Q1 2025	CUE Cue Biopharma	-$0.14	-$0.17	-$0.03	-$0.17	$0.90 million	$0.42 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	N/A	1.03	1.03
ELDN Eledon Pharmaceuticals	N/A	13.90	13.91
ESPR Esperion Therapeutics	N/A	1.18	0.81
TVGN Semper Paratus Acquisition	N/A	0.35	0.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
ELDN Eledon Pharmaceuticals	56.77%
ESPR Esperion Therapeutics	47.39%
TVGN Semper Paratus Acquisition	N/A

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	10.78%
ELDN Eledon Pharmaceuticals	12.30%
ESPR Esperion Therapeutics	1.70%
TVGN Semper Paratus Acquisition	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	60	75.35 million	67.23 million	Optionable
ELDN Eledon Pharmaceuticals	10	59.88 million	52.52 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
TVGN Semper Paratus Acquisition	3	183.89 million	49.21 million	N/A

CUE, ELDN, ESPR, and TVGN Headlines

Recent News About These Companies

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch

July 16 at 11:57 AM | globenewswire.com

Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

July 14 at 9:30 AM | globenewswire.com

Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation

July 10, 2025 | globenewswire.com

Tevogen Bio Holdings Inc News (TVGN) - Investing.com

July 8, 2025 | investing.com

Semper Paratus Acquisition (NASDAQ:TVGN) Shares Down 2.4% - Here's Why

July 2, 2025 | marketbeat.com

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

June 30, 2025 | globenewswire.com

Semper Paratus Acquisition's (TVGN) "Buy" Rating Reaffirmed at D. Boral Capital

June 18, 2025 | marketbeat.com

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

June 18, 2025 | globenewswire.com

Tevogen Bio

June 17, 2025 | thepharmaletter.comT

Tevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars Initiatives

June 12, 2025 | nasdaq.com

Tevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from Microsoft

June 10, 2025 | nasdaq.com

Tevogen Bio doubles Warren HQ footprint for AI expansion

June 10, 2025 | njbiz.comN

Ambitious Tevogen makes expansion announcement

June 10, 2025 | thepharmaletter.comT

Ryan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

June 10, 2025 | insidertrades.com

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

June 9, 2025 | globenewswire.com

tevogen bio expands office lease in new jersey with key amendment

June 5, 2025 | investing.com

Tevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijziging

June 4, 2025 | nl.investing.com

Tevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapie

June 1, 2025 | nl.investing.com

Tevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI Technologies

May 30, 2025 | quiverquant.comQ

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

May 30, 2025 | globenewswire.com

Tevogen Peports Plans to Increase the Target Population for TVGN 489

May 26, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, ELDN, ESPR, and TVGN Company Descriptions

Cue Biopharma NASDAQ:CUE

$0.86 +0.16 (+22.29%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$0.84 -0.02 (-1.75%)

As of 07/16/2025 07:59 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Eledon Pharmaceuticals NASDAQ:ELDN

$3.78 -0.07 (-1.82%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$3.77 -0.01 (-0.26%)

As of 07/16/2025 07:58 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Esperion Therapeutics NASDAQ:ESPR

$1.12 -0.01 (-0.88%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$1.13 +0.01 (+0.89%)

As of 07/16/2025 07:59 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Semper Paratus Acquisition NASDAQ:TVGN

$1.23 +0.03 (+2.50%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$1.24 +0.01 (+0.81%)

As of 07/16/2025 07:32 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time